Early on in the COVID-19 pandemic, the term “antibodies” was tucked into the various conversations about vaccines and treatment options that swirled through public and scientific communities alike. Could they help treat the sick? When could they be retrieved from recovered COVID-19 patients? How should they be administered? The conversations and possibilities often outpaced the explanations.
As global research efforts continue looking at a variety of treatment and preventative options, we are seeing more antibody trials coming online — including here through Baylor Scott & White Research Institute.
To read the full story, visit the Baylor Scott & White blog.